Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. ...(ies. Measurement of serum lipids should...),Health

during PRISTIQ treatment.

* On discontinuation, adverse events, some of which may be serious, have

been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt

discontinuation of PRISTIQ has been associated with the appearance of

new symptoms. Patients should be monitored for symptoms when

discontinuing treatment. A gradual reduction in dose (by giving 50 mg

of PRISTIQ less frequently) rather than abrupt cessation is recommended

whenever possible.

* Dosage adjustment (50 mg every other day) is necessary in patients with

severe renal impairment or end-stage renal disease (ESRD). The dose

should not be escalated in patients with moderate or severe renal

impairment or ESRD.

* Products containing desvenlafaxine and products containing venlafaxine

should not be used concomitantly with PRISTIQ.

* Hyponatremia may occur as a result of treatment with SSRIs and SNRIs,

including PRISTIQ. Discontinuation of PRISTIQ should be considered in

patients with symptomatic hyponatremia.

* Interstitial lung disease and eosinophilic pneumonia associated with

venlafaxine (the parent drug of PRISTIQ) therapy have been rarely

reported.

Adverse Reactions

* The most commonly observed adverse reactions in patients taking PRISTIQ

vs placebo for MDD in short-term fixed-dose premarketing studies

(incidence greater than or equal to 5% and twice the rate of placebo in

the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%),

hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased

appetite (5% vs 2%).

For full prescribing information for PRISTIQ, please go to http://www.Pristiq.com.

Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth,
'/>"/>